Oxford BioMedica (OTCMKTS:OXBDF) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Oxford BioMedica (OTCMKTS:OXBDF) from a hold rating to a sell rating in a research note released on Thursday, Zacks.com reports.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Separately, HC Wainwright reaffirmed a buy rating and issued a $14.50 price target on shares of Oxford BioMedica in a research note on Wednesday, September 4th.



OTCMKTS OXBDF opened at $6.82 on Thursday. Oxford BioMedica has a 1-year low of $6.80 and a 1-year high of $12.20. The company has a market capitalization of $459.40 million, a PE ratio of 45.47 and a beta of 0.79. The firm’s fifty day simple moving average is $8.07 and its 200-day simple moving average is $8.80.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Featured Story: What is the definition of a trade war?

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.